<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00530517</url>
  </required_header>
  <id_info>
    <org_study_id>ZX001-0701</org_study_id>
    <nct_id>NCT00530517</nct_id>
  </id_info>
  <brief_title>A Study on the Usability of the Needle-Free Intraject® System in Adult Patients During Acute Migraine Attack</brief_title>
  <official_title>A Multi-Center, Open-Label, Single-Dose, Single-Arm Study to Evaluate the Usability of Subcutaneously Administered Sumatriptan Delivered Via the Intraject® System in Adult Patients During Acute Migraine Attack</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zogenix, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zogenix, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Intraject is a needle-free, single use, disposable, subcutaneous delivery system pre-filled
      with 6mg Sumatriptan to be used by patients to treat acute migraine treatment. Study
      participation will last one month and include 2 doctor visits and 2-4 phone calls.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will evaluate how patients will interact with the needle-free Intraject system
      during actual self-administration to the abdomen or thigh for treatment of migraine headache
      while outside the clinic.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">October 2007</completion_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the usability of sumatriptan delivered subcutaneously via the Intraject system in adult patients during acute migraine attack</measure>
    <time_frame>30 Days</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Migraine Headache</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Intraject Sumatriptan</intervention_name>
    <description>needle-free, single use, disposable, subcutaneous delivery system pre-filled with 6mg Sumatriptan</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have a diagnosis of migraine with an average of ≥2 to ≤6 attacks/month

          -  Female subjects of child-bearing potential must agree to use acceptable birth control

          -  Have abdominal or thigh injection sites that have sufficient subcutaneous tissue for
             needle-free injection

          -  Fluent in the spoken and written English language

          -  Provide written informed consent to participate in the study and be willing to comply
             with the study procedures

          -  Access to a telephone for call center interactions

        Exclusion Criteria:

          -  A history, symptoms, or signs of ischemic cardiac, cerebrovascular, or peripheral
             vascular syndromes including ischemic or vasospastic coronary artery disease

          -  Other significant underlying cardiovascular diseases including uncontrolled
             hypertension

          -  Hemiplegic or basilar migraine

          -  A history or diagnosis of severe hepatic or renal impairment

          -  A history of epilepsy or seizure or other serious neurologic condition

          -  A history of allergy, anaphylaxis, or hypersensitivity to sumatriptan or any of its
             components or similar drugs

          -  A history of scleroderma (systemic sclerosis) or any skin condition that may adversely
             affect the injection or absorption of subcutaneously administered medications

          -  Tattoos in the thigh or abdominal area that are large enough to restrict injection
             site selection and/or evaluation

          -  Birthmark or other significant skin discoloration in the thigh or abdominal area large
             enough to restrict injection site selection and/or evaluation

          -  Pregnancy or breast-feeding

          -  Have participated in a clinical trial or receipt of an experimental therapy within 30
             days prior to dosing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan Brandes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nashville Neuroscience Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2007</study_first_submitted>
  <study_first_submitted_qc>September 13, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 17, 2007</study_first_posted>
  <last_update_submitted>February 7, 2008</last_update_submitted>
  <last_update_submitted_qc>February 7, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 18, 2008</last_update_posted>
  <responsible_party>
    <name_title>Stephen J. Farr, Ph.D/ President and COO</name_title>
    <organization>Zogenix, Inc</organization>
  </responsible_party>
  <keyword>migraine</keyword>
  <keyword>sumatripatan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
    <mesh_term>Headache</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sumatriptan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

